

ORGANIZING COMMITTEE

M. Bialer, Israel

S.I. Johannessen, Norway

R.H. Levy, USA

E. Perucca, Italy

T. Tomson, Sweden

H.S. White, USA

PROGRAM (updated February 23, 2016)

SUNDAY, JUNE 26, 2016

16:00 – 16:15 OPENING SESSION

OPENING REMARKS AND GREETINGS

M. Bialer, Organizing Committee, Israel

GREETINGS

E. Perucca, Organizing Committee and ILAE President, Italy

16:15 PLENARY LECTURES

16:15 EPIDEMIOLOGY OF EPILEPSY (COVERING DIFFERENT SEIZURE TYPES AND EPILEPSIES)

E. Beghi, Italy

16:35 Discussion

16:45 PREDICTORS OF ADVERSE EFFECTS

P. Ryvlin, France

17:05 Discussion

17:15 DEBATE 1

17:15 HAS THE PROBABILITY OF ACHIEVING SEIZURE FREEDOM INCREASED SIGNIFICANTLY IN THE LAST TWO DECADES?

YES: J. A. French, USA

NO: M.J. Brodie, UK

17:35 Discussion

17:45 PLENARY LECTURES

17:45 DIFFICULTIES/CHALLENGES OF ADVANCING NEW EPILEPSY THERAPIES

R. Porter, University of Pennsylvania, USA


18:05 Discussion

18:15 WHAT ARE THE MOST IMPORTANT “ERRORS” (PREDICTION FAILURES) IN PRECLINICAL DEVELOPMENT? WHAT DO THEY TEACH?

H. Klitgaard, Belgium

18:35 Discussion

20:00 Welcome Reception



ORGANIZING COMMITTEE

M. Bialer, Israel

S.I. Johannessen, Norway

R.H. Levy, USA

E. Perucca, Italy

T. Tomson, Sweden

H.S. White, USA

PROGRAM (updated February 23, 2016)


MONDAY, JUNE 27, 2016

08:00 INNOVATIVE EMERGENCY TREATMENTS

- 08:00 INTRANASAL MIDAZOLAM (USL261)
W. E. Pullman, *Upsher-Smith Laboratories, Inc., USA*
- 08:20 INTRANASAL DIAZEPAM
D. Squillacote, *Acorda Therapeutics, Inc., USA*
- 08:40 BUCCAL MIDAZOLAM
S. Paille, *Shire International GmbH, Switzerland*
- 09:00 IV CARBAMAZEPINE
J. Isojärvi, *Lundbeck Inc., USA*
- 09:20 IV BRIVARACETAM
UCB Pharma, Belgium
Presented by **E. Trink**, *Paracelsus Medical University, Austria*
- 09:40 PROPOFOL HEMISUCCINATE
Epalex Corporation
Presented by **M. A. Rogawski**, *University of California, Davis, USA*
- 10:00 Coffee

10:00 PLENARY SESSION
HOW TO GET PHARMA INTERESTED IN AED DEVELOPMENT?

- 10:00 **G. Guy, Chairman and Founder**, *G. W. Pharmaceuticals, UK*
- 10:15 Discussion
- 10:20 **R. Cohen, President & CEO**, *Acorda Therapeutics, USA*
- 10:35 Discussion
- 10:40 **W. E. Pullman, Chief Scientific Officer**, *Upsher-Smith Laboratories, Inc., USA*
- 10:55 Discussion
- 11:00 General Discussion



ORGANIZING COMMITTEE

M. Bialer, Israel
S.I. Johannessen, Norway
R.H. Levy, USA
E. Perucca, Italy
T. Tomson, Sweden
H.S. White, USA

PROGRAM (updated February 23, 2016)


MONDAY, JUNE 27, 2016 (Continued)

11:30 DRUGS IN DEVELOPMENT

- 11:30 ACETONE ANALOGS
J. Andrews, *Ketogen Pharma Inc.*, Canada
- 11:50 ADENOSINE
D. Boison, *Legacy Research Institute*, USA
- 12:10 SAGE-547 FOR SUPER-REFRACTORY STATUS EPILEPTICUS
S. J. Kanes, *Sage Therapeutics*, USA
- 12:30 Lunch

13:30 DRUGS IN DEVELOPMENT CONTINUED

- 13:30 BMN 190
BioMarin Pharmaceutical Inc., USA
Presented by **N. Specchio**, *Bambino Gesù Children's Hospital*
- 13:50 BRIVARACETAM
J. Whitesides, *UCB Pharma*, Belgium
- 14:10 BUMETANIDE and its DERIVATIVES
Presented by **W. Löscher**, *University of Hannover*, Germany
- 14:30 CANNABIDIOL
K. W. Sommerville & K. VanLandingham, *GW Pharmaceuticals*, UK
- 14:50 CANNABIDIVARIN
K. W. Sommerville, *GW Pharmaceuticals*, UK
- 15:10 Coffee
- 15:40 EVEROLIMUS
Presented by **P. Curatolo**, "Tor Vergata" *University Hospital*, Rome, Italy
- 16:00 FENFLURAMINE
G. M. Farfel, *Zogenix Pharmaceutical*, USA
- 16:20 FV-082
M. Slassi, *Fluorinov Pharma Inc.*, Canada
- 16:40 GANAXOLONE
A. Patroneva, *Marinus Pharmaceuticals Inc.*, USA
- 17:00 ISOXYLITONE
M. Poulter, *OB Pharmaceuticals*, Canada



ORGANIZING COMMITTEE

M. Bialer, Israel

S.I. Johannessen, Norway

R.H. Levy, USA

E. Perucca, Italy

T. Tomson, Sweden

H.S. White, USA

PROGRAM (updated February 23, 2016)

TUESDAY, JUNE 28, 2016

08:30 – 09:00 DEBATE 2

08:30 IS KNOWLEDGE OF MECHANISM OF ACTION ESSENTIAL FOR THE DEVELOPMENT OF NEW AEDs?

YES: W. Löscher, Germany

NO: M. A. Rogawski, USA

08:50 Discussion

09:00 PLENARY LECTURE

09:00 REGULATORY ASPECTS FOR APPROVAL OF NEW AEDs IN EUROPE

S. Prilla, EMA, UK

09:20 Discussion

09:30 DRUGS IN DEVELOPMENT CONTINUED

09:30 HUPERZINE A (BIS-001)

S. D. Collins, Biscayne Pharmaceuticals, USA

09:50 MINOCYCLINE

Presented by **S. Koh**, Northwestern University, USA

10:10 Coffee

10:40 NAX 810-2

C. Metcalf, NeuroAdjuvants, USA

11:00 PITOLISANT (TIPROLISANT)


D. Kasteleijn-Nolst-Trenite, University of Rome "Sapienza" II, Italy

11:20 PRX 0023 (Nalutozan)

W. H. Theodore, NINDS, NIH, USA

11:40 SAGE-689/217-NEXT GENERATION NEUROACTIVE STEROID GABA-PAMS-DEVELOPMENT PROGRESS UPDATE

A. J. Robichaud, Sage Therapeutics (USA)



ORGANIZING COMMITTEE

M. Bialer, Israel
S.I. Johannessen, Norway
R.H. Levy, USA
E. Perucca, Italy
T. Tomson, Sweden
H.S. White, USA


PROGRAM (updated February 23, 2016)

TUESDAY, JUNE 28, 2016 (Continued)

- 12:00 2-DEOXY-(D)-GLUCOSE
 Presented by **T. P. Sutula**, University of Wisconsin, USA
- 12:20 VALNOCTAMIDE and sec-BUTYLPROPYLACETAMIDE (SPD)
 Presented by **M. Bialer**, The Hebrew University of Jerusalem, Israel
- 12:40 Lunch
- 13:40 YKP3089
M. Kamin, SK Life Science, USA
- 14:00 IMEPITOIN
Boehringer-Ingelheim, Germany
 Presented by **W. Löscher**, University of Hannover, Germany

14:20 PROGRESS REPORT ON SECOND-GENERATION TREATMENTS

- 14:20 CLOBAZAM
J. Isojärvi, *Lundbeck Inc., USA*
- 14:40 ESLICARBAZEPINE ACETATE
BIAL Portugal
 Presented by **E. Trinka**, Paracelsus Medical University, Austria
- 15:00 Coffee
- 15:30 LACOSAMIDE
K. J. Werhahn, *UCB Pharma, Belgium*
- 15:50 PERAMPANEL
A. Laurenza, *Eisai, Inc., USA*
- 16:10 PREGABALIN
V. Pitman, *Pfizer Inc., USA*
- 16:30 STIRIPENTOL
Biocodex, France
 Presented by **E. Wirrell**, The Mayo Clinics, USA
- 16:50 VIGABATRIN
J. Isojärvi, *Lundbeck Inc., USA*



ORGANIZING COMMITTEE

M. Bialer, Israel

S.I. Johannessen, Norway

R.H. Levy, USA

E. Perucca, Italy

T. Tomson, Sweden

H.S. White, USA

PROGRAM (updated February 23, 2016)

WEDNESDAY, JUNE 29, 2016

08:00 PLENARY LECTURE

08:00 ALTERNATIVE THERAPIES AND APPROACHES

M. Walker, UK

08:20 Discussion

08:30 NEW MEDICAL DEVICES AND NEUROMODULATION

08:30 WHY DO WE NEED RELIABLE SEIZURE DETECTION SYSTEMS?

P. Ryvlin, France

08:50 EEG-BASED SEIZURE DETECTION SYSTEMS IN EPILEPSY

J. Gotman, Canada

09:10 ECG-BASED SEIZURE DETECTION SYSTEMS IN EPILEPSY

C. Elger, Germany

09:30 CARDIAC-BASED NEW VAGAL NERVE STIMULATION

K. Vonck, Belgium

09:50 Coffee

10:20 SEIZURE RESPONSIVE VAGUS NERVE STIMULATION (**Cyberonics**)

P. Boon, *Cyberonics*, USA

10:40 TRANSCUTANEOUS VAGUS NERVE STIMULATION (tVNS)

F. Rosenow, University Hospital Frankfurt, Germany

11:00 TRIGEMINAL NERVE STIMULATION

J. Serratos, Autonomous University of Madrid, Spain

11:20 DEEP BRAIN STIMULATION FOR EPILEPSY

J. Giftakis, *Medtronic Neuromodulation*, USA

11:40 RESPONSIVE CORTICAL STIMULATION (**Neuropace**)

M. Morrell, *Neuropace*, USA

12:00 End of meeting and concluding remarks

